MCID: EWN002
MIFTS: 45

Ewing's Family of Tumors

Categories: Rare diseases, Neuronal diseases, Bone diseases, Genetic diseases

Aliases & Classifications for Ewing's Family of Tumors

MalaCards integrated aliases for Ewing's Family of Tumors:

Name: Ewing's Family of Tumors 50
Neuroectodermal Tumor, Primitive 69
Primitive Neuroectodermal Tumor 50
Ewing Family of Tumors 50
Ewing’s Tumor of Bone 50
Extraosseous Ewing’s 50
Askin’s Tumor 50

Classifications:



Summaries for Ewing's Family of Tumors

MalaCards based summary : Ewing's Family of Tumors, also known as neuroectodermal tumor, primitive, is related to extraosseous ewing's sarcoma and askin's tumor. An important gene associated with Ewing's Family of Tumors is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are GPCR Pathway and PEDF Induced Signaling. The drugs Darunavir and Dolutegravir have been mentioned in the context of this disorder. Affiliated tissues include bone, nk cells and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cellular

Related Diseases for Ewing's Family of Tumors

Diseases related to Ewing's Family of Tumors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 116)
id Related Disease Score Top Affiliating Genes
1 extraosseous ewing's sarcoma 12.4
2 askin's tumor 12.3
3 supratentorial primitive neuroectodermal tumor 12.3
4 cerebral primitive neuroectodermal tumor 12.3
5 intracranial primitive neuroectodermal tumor 12.2
6 primitive neuroectodermal tumor of the cervix uteri 12.2
7 extraosseous ewings sarcoma-primitive neuroepithelial tumor 11.2
8 ewing sarcoma 11.0
9 kasznica carlson coppedge syndrome 10.8 FLI1 MTOR
10 venous hemangioma 10.6 KIT KITLG
11 blunt duct adenosis of breast 10.6 EPO EWSR1
12 hypocalciuric hypercalcemia, type iii 10.6 EPO KITLG
13 cutaneous solitary mastocytoma 10.6 KIT KITLG
14 adult brainstem gliosarcoma 10.6 KIT KITLG
15 colon neuroendocrine neoplasm 10.5 ERBB2 KIT
16 parasitic conjunctivitis 10.5 EPO ERBB2
17 cough variant asthma 10.5 KIT KITLG
18 combat disorder 10.4 CDKN2A MTOR
19 erythropoietin polycythemia 10.4 EPO EPOR
20 clear cell chondrosarcoma 10.4 CDKN2B EWSR1
21 rhabdoid cancer 10.4 KIT KITLG
22 lung clear cell-sugar-tumor 10.4 CDK4 EWSR1 KIT
23 skeletal tuberculosis 10.4 CDKN2A ERBB2
24 atrioventricular septal defect 2 10.4 EPO EPOR
25 gestational choriocarcinoma 10.4 CDK4 EWSR1 KIT
26 spindle cell sarcoma 10.4 CDK4 EWSR1 KIT
27 testis seminoma 10.4 CDKN2A ERBB2
28 vulva squamous cell carcinoma 10.4 CDKN2A ERBB2
29 epidural neoplasm 10.3 CDK4 CDKN2A
30 disseminated intravascular coagulation 10.3 EPO EPOR
31 dextrocardia with situs inversus 10.3 CSF3 EWSR1 FLI1
32 duodenum cancer 10.3 CDKN2A FAS
33 myotonia congenita 10.3 CDKN2A ERBB2
34 kidney clear cell sarcoma 10.3 ERBB2 KIT
35 superficial basal cell carcinoma 10.3 CDKN2A KIT
36 methemoglobinemia 10.3 EPO EPOR
37 leydig cell tumor 10.3 CDK4 CDKN2B EWSR1
38 cutaneous liposarcoma 10.3 CDK4 KIT
39 duane anomaly mental retardation 10.2 CSF3 EPOR
40 acute leukemia 10.2 EPO EPOR FLI1
41 diffuse meningeal melanocytosis 10.2 CDKN2A KIT
42 kala-azar 1 10.2 EWSR1 FLI1 KIT KITLG
43 vulval paget's disease 10.2 CDKN2A KIT
44 afferent loop syndrome 10.2 EPO EPOR KITLG
45 orbital lymphoma 10.2 CDKN2A ERBB2
46 plummer vinson syndrome 10.2 CDKN2A MTOR
47 neurofibroma of the esophagus 10.2 CDK4 CDKN2A
48 dmd-related dilated cardiomyopathy 10.2 ERBB2 MTOR
49 skin lipoma 10.1 CDK4 RB1
50 penis paget's disease 10.1 CDKN2A CDKN2B

Graphical network of the top 20 diseases related to Ewing's Family of Tumors:



Diseases related to Ewing's Family of Tumors

Symptoms & Phenotypes for Ewing's Family of Tumors

GenomeRNAi Phenotypes related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.16 KIT
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.16 MTOR EWSR1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.16 MTOR
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.16 CDK4
5 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.16 EWSR1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.16 EWSR1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.16 EWSR1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.16 EWSR1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.16 EWSR1 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.16 KIT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.16 MTOR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.16 EWSR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.16 KIT
14 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.16 EWSR1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.16 CDK4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.16 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.16 MTOR EWSR1 KIT CDK4
18 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.16 CDK4
19 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.16 EWSR1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.16 MTOR
21 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.16 EWSR1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.16 MTOR KIT CDK4
23 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.16 KIT
24 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.16 EWSR1 KIT
25 Increased transferrin (TF) endocytosis GR00363-A 9.32 CDKN2A MTOR CDKN2B EPO EPOR ERBB2

MGI Mouse Phenotypes related to Ewing's Family of Tumors:

44 (show all 23)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 CDK4 CDKN2B CDKN2A RB1 MTOR ERBB2
2 cardiovascular system MP:0005385 10.35 CDK4 CDKN2A RB1 MTOR ERBB2 EPO
3 hematopoietic system MP:0005397 10.35 CDKN2B CDKN2A CSF3 EPO CDK4 RB1
4 immune system MP:0005387 10.33 CDKN2B CDKN2A CSF3 CDK4 RB1 MTOR
5 homeostasis/metabolism MP:0005376 10.3 CDK4 CDKN2B CDKN2A RB1 MTOR ERBB2
6 embryo MP:0005380 10.29 CDKN2A EPO CDK4 RB1 MTOR ERBB2
7 endocrine/exocrine gland MP:0005379 10.28 CDK4 CDKN2B CDKN2A RB1 MTOR ERBB2
8 growth/size/body region MP:0005378 10.27 CDKN2A CDK4 KITLG RB1 MTOR ERBB2
9 mortality/aging MP:0010768 10.27 CDK4 CDKN2B CDKN2A RB1 MTOR ERBB2
10 integument MP:0010771 10.24 CDKN2B CSF3 CDKN2A CDK4 RB1 ERBB2
11 liver/biliary system MP:0005370 10.16 CDKN2A CDK4 RB1 EPO EPOR FAS
12 digestive/alimentary MP:0005381 10.14 CDK4 CDKN2A RB1 ERBB2 KITLG FAS
13 nervous system MP:0003631 10.13 CDK4 CDKN2A RB1 MTOR ERBB2 EPOR
14 neoplasm MP:0002006 10.11 CDKN2B CDKN2A CDK4 RB1 FAS ERBB2
15 muscle MP:0005369 10.08 CDK4 CDKN2A RB1 MTOR ERBB2 EPO
16 limbs/digits/tail MP:0005371 10 KITLG RB1 EPO ERBB2 FAS KIT
17 normal MP:0002873 9.97 CDK4 RB1 MTOR ERBB2 EPO EPOR
18 no phenotypic analysis MP:0003012 9.88 CDKN2A CDKN2B MTOR RB1 EPOR KIT
19 pigmentation MP:0001186 9.8 CDK4 CDKN2A RB1 FAS KIT KITLG
20 renal/urinary system MP:0005367 9.8 CDK4 CDKN2B CSF3 RB1 MTOR FAS
21 reproductive system MP:0005389 9.76 CDKN2A CDK4 CDKN2B RB1 ERBB2 KITLG
22 respiratory system MP:0005388 9.56 CDKN2A RB1 MTOR ERBB2 EPO EPOR
23 skeleton MP:0005390 9.23 CDKN2A KITLG RB1 MTOR EPO ERBB2

Drugs & Therapeutics for Ewing's Family of Tumors

Drugs for Ewing's Family of Tumors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 292)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
2 Dolutegravir Approved Phase 4 1051375-16-6 54726191
3
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
4 Anti-HIV Agents Phase 4,Phase 2,Phase 1
5 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1
7 Antiviral Agents Phase 4,Phase 2,Phase 1
8 HIV Protease Inhibitors Phase 4,Phase 2
9
protease inhibitors Phase 4,Phase 2
10 Cytochrome P-450 CYP3A Inhibitors Phase 4
11 Cytochrome P-450 Enzyme Inhibitors Phase 4
12 HIV Integrase Inhibitors Phase 4
13 Integrase Inhibitors Phase 4
14
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
15
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
16
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
17
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
18
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
19
Mesna Approved Phase 3,Phase 2,Phase 1 3375-50-6 598
20
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
21
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
22
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
23
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
24
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
25
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 498142 38904
26
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
27
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
28
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
29
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
30
Zoledronic acid Approved Phase 3,Phase 1 118072-93-8 68740
31
Cyproheptadine Approved Phase 3 129-03-3 2913
32
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
33 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
34
Treosulfan Investigational Phase 3 299-75-2 9296
35 Alkylating Agents Phase 3,Phase 2,Phase 1
36 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
37 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
38 Antimitotic Agents Phase 3,Phase 2,Phase 1
39 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
40 Antirheumatic Agents Phase 3,Phase 2,Phase 1
41
Cobalt Phase 3,Phase 2 7440-48-4 104729
42 Etoposide phosphate Phase 3,Phase 2,Phase 1
43 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
44 Isophosphamide mustard Phase 3,Phase 2,Phase 1
45 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
46 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
47 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
48 Liver Extracts Phase 3,Phase 2,Phase 1
49 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
50 Antineoplastic Agents, Hormonal Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 265)

id Name Status NCT ID Phase Drugs
1 Dolutegravir and Darunavir Evaluation in Adults Failing Therapy Recruiting NCT03017872 Phase 4 N(t)RTIs;Dolutegravir;Darunavir;Ritonavir
2 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
3 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
4 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
5 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
6 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
7 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
8 Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma Recruiting NCT02063022 Phase 3 Standard treatment (as per protocol ISG SSG III);Intensified chemotherapy
9 Study in Localized and Disseminated Ewing Sarcoma Recruiting NCT00987636 Phase 3 Zoledronic acid;Busulfan;Treosulfan
10 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Vincristine Sulfate
11 Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer Recruiting NCT02856048 Phase 2, Phase 3 Triptorelin (GnRHa) + Chemotherapy
12 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3 vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide;ifosfamide;etoposide;topotecan hydrochloride
13 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
14 Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients Withdrawn NCT01734863 Phase 3
15 Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma Withdrawn NCT00334867 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate
16 Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults Unknown status NCT01696669 Phase 2 Chemotherapy
17 Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas Unknown status NCT00998361 Phase 2
18 Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse Unknown status NCT00180947 Phase 2 Vinorelbine, cyclofosfamide
19 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
20 Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status NCT00084695 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
21 Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy Completed NCT01222767 Phase 2 Zalypsis
22 Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor Completed NCT00062205 Phase 2 imatinib mesylate
23 Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors Completed NCT00560235 Phase 1, Phase 2 CP-751,871
24 Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors Completed NCT00070109 Phase 2 trabectedin
25 Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors Completed NCT00061893 Phase 2 celecoxib;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vinblastine sulfate;vincristine sulfate;MESNA;Filgrastim
26 Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma Completed NCT01583543 Phase 2 Olaparib
27 New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma Completed NCT00001335 Phase 2 ADR-529;Topotecan;G-CSF
28 Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma Completed NCT02546544 Phase 2 Linsitinib
29 Aerosol L9-NC and Temozolomide in Ewing's Sarcoma Completed NCT00492141 Phase 1, Phase 2 Temozolomide;L9-NC
30 Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma Completed NCT00276692 Phase 2 irinotecan hydrochloride
31 Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma Completed NCT00516295 Phase 2 topotecan hydrochloride;vincristine sulfate;cyclophosphamide
32 Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma Completed NCT00470275 Phase 2 cytarabine
33 Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors Completed NCT00357396 Phase 2 busulfan;melphalan;thiotepa
34 Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor Completed NCT00002643 Phase 2 amifostine trihydrate;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate
35 Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma Completed NCT00073983 Phase 2 docetaxel;gemcitabine hydrochloride
36 Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone Completed NCT00006234 Phase 1, Phase 2
37 Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma Completed NCT00003667 Phase 2 cyclophosphamide;dexrazoxane hydrochloride;disaccharide tripeptide glycerol dipalmitoyl;doxorubicin hydrochloride;vincristine sulfate
38 Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor Completed NCT00055952 Phase 2 exatecan mesylate
39 Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
40 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Completed NCT00668148 Phase 2
41 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
42 QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors Completed NCT00563680 Phase 2 AMG 479
43 A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas Completed NCT00001566 Phase 2 indinavir sulfate
44 A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas Completed NCT00001564 Phase 2 EF-1 Peptide;EF-2 Peptide;PXFK Peptide;E7 Peptide;IL-2;IL-4;GM-CSF;CD40 Ligand
45 Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas Completed NCT00165139 Phase 2 Vincristine;Cyclophosphamide;Adriamycin;Etoposide (VP-16);Cisplatin;Carboplatin;Melphalan;Ifosfamide;G-CSF (granulocyte-colony stimulating factor);Mesna
46 A Study of Pemetrexed in Children With Recurrent Cancer Completed NCT00520936 Phase 2 pemetrexed
47 Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure Completed NCT01136499 Phase 2 LBH589 (Panobinostat®)
48 A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone Completed NCT01288573 Phase 1, Phase 2 plerixafor;plerixafor;plerixafor
49 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
50 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01154816 Phase 2 Alisertib

Search NIH Clinical Center for Ewing's Family of Tumors

Genetic Tests for Ewing's Family of Tumors

Anatomical Context for Ewing's Family of Tumors

MalaCards organs/tissues related to Ewing's Family of Tumors:

39
Bone, Nk Cells, Testes, Lung, Kidney, Brain, T Cells

Publications for Ewing's Family of Tumors

Articles related to Ewing's Family of Tumors:

(show all 13)
id Title Authors Year
1
Ewing's family of tumors of the sinonasal tract and maxillary bone. ( 21107767 )
2011
2
High-dose chemotherapy and stem cell rescue for high-risk Ewing's family of tumors. ( 21342043 )
2011
3
Immunophenotypic profile of biomarkers related to anti-apoptotic and neural development pathways in the Ewing's family of tumors (EFT) and their therapeutic implications. ( 17695539 )
2007
4
Single center experience of treatment of Ewing's family of tumors in Japan. ( 16437346 )
2006
5
Prognostic and therapeutic targets in the Ewing's family of tumors (PROTHETS). ( 17163151 )
2006
6
EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. ( 15930281 )
2005
7
High-dose therapy and stem-cell rescue for Ewing's family of tumors in second remission. ( 15781877 )
2005
8
Megatherapy and stem cell transplantation for Ewing's family of tumors: a critical review of current literature. ( 15125709 )
2004
9
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. ( 12972518 )
2003
10
Single center experience of a new intensive induction therapy for ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties. ( 12885818 )
2003
11
Ewing's family of tumors involving structures related to the central nervous system: a review. ( 10742406 )
2000
12
Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital. ( 10458232 )
1999
13
Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. ( 9850016 )
1998

Variations for Ewing's Family of Tumors

Expression for Ewing's Family of Tumors

Search GEO for disease gene expression data for Ewing's Family of Tumors.

Pathways for Ewing's Family of Tumors

Pathways related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

(show all 38)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.61 CDK4 CDKN2A CDKN2B EPOR ERBB2 KIT
2
Show member pathways
13.53 CSF3 EPO EPOR ERBB2 FAS KIT
3
Show member pathways
13.53 CDK4 CDKN2A CDKN2B CSF3 EPOR ERBB2
4
Show member pathways
13.29 CSF3 EPOR ERBB2 FAS KIT KITLG
5
Show member pathways
12.48 CDK4 CDKN2A CDKN2B RB1
6 12.45 FAS FLI1 KIT KITLG
7 12.34 CDK4 CDKN2A CDKN2B RB1
8
Show member pathways
12.33 CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
9
Show member pathways
12.28 CDK4 CDKN2A FAS RB1
10
Show member pathways
12.26 CDK4 CDKN2A CDKN2B RB1
11 12.19 CDK4 CDKN2A CDKN2B RB1
12
Show member pathways
12.16 CDK4 ERBB2 MTOR RB1
13 12.16 CDK4 CDKN2A CDKN2B KITLG RB1
14 12.14 CDK4 CSF3 EPO EPOR FAS KIT
15
Show member pathways
12.1 CDK4 CDKN2A CDKN2B RB1
16
Show member pathways
12.09 CSF3 EPO EPOR MTOR
17
Show member pathways
12.03 EPO EPOR KIT KITLG
18 12 ERBB2 KIT KITLG
19 11.94 CDK4 CDKN2A FAS MTOR
20 11.87 CDK4 CDKN2A CDKN2B ERBB2 FAS KIT
21 11.86 CDKN2A MTOR RB1
22 11.85 CSF3 EPO KIT KITLG
23 11.82 EPO ERBB2 MTOR
24 11.8 CDK4 CDKN2A MTOR RB1
25 11.79 EPO EPOR MTOR
26 11.75 CDK4 CDKN2B RB1
27 11.67 CDKN2A ERBB2 FAS
28 11.63 CDK4 MTOR RB1
29 11.59 ERBB2 KIT MTOR
30 11.54 CSF3 EPO EPOR KIT KITLG
31 11.53 CDK4 CDKN2A ERBB2 RB1
32 11.46 CDKN2A FAS RB1
33 11.42 EPO KIT KITLG
34 11.38 CDK4 CDKN2B RB1
35 11.24 CSF3 EPO FLI1 KITLG
36 11.18 CDK4 CDKN2A CDKN2B
37 11.02 CDKN2A RB1
38 10.87 KIT KITLG

GO Terms for Ewing's Family of Tumors

Biological processes related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

(show all 25)
id Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.97 CDK4 EPO EPOR ERBB2 FAS KIT
2 regulation of transcription from RNA polymerase II promoter GO:0006357 9.89 EPO ERBB2 FLI1 KIT RB1
3 positive regulation of cell proliferation GO:0008284 9.85 CDK4 CSF3 EPO KIT KITLG
4 cytokine-mediated signaling pathway GO:0019221 9.8 CSF3 EPOR KIT
5 positive regulation of gene expression GO:0010628 9.78 ERBB2 KIT MTOR
6 phosphatidylinositol phosphorylation GO:0046854 9.75 ERBB2 KIT KITLG
7 G1/S transition of mitotic cell cycle GO:0000082 9.74 CDK4 CDKN2A RB1
8 phosphorylation GO:0016310 9.73 CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.71 CSF3 KITLG MTOR
10 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.69 ERBB2 KIT KITLG
11 negative regulation of phosphorylation GO:0042326 9.62 CDKN2A CDKN2B
12 positive regulation of Ras protein signal transduction GO:0046579 9.61 EPO KITLG
13 positive regulation of translation GO:0045727 9.61 CDK4 ERBB2 MTOR
14 response to hyperoxia GO:0055093 9.6 CDK4 EPO
15 megakaryocyte development GO:0035855 9.59 FLI1 KIT
16 embryonic hemopoiesis GO:0035162 9.58 KIT KITLG
17 positive regulation of MAP kinase activity GO:0043406 9.58 ERBB2 KIT KITLG
18 hepatocyte apoptotic process GO:0097284 9.56 FAS RB1
19 positive regulation of transcription from RNA polymerase III promoter GO:0045945 9.55 ERBB2 MTOR
20 somatic stem cell division GO:0048103 9.52 CDKN2A KIT
21 ectopic germ cell programmed cell death GO:0035234 9.48 KIT KITLG
22 cell cycle arrest GO:0007050 9.46 CDKN2A CDKN2B MTOR RB1
23 negative regulation of immature T cell proliferation in thymus GO:0033088 9.32 CDKN2A ERBB2
24 phosphatidylinositol-mediated signaling GO:0048015 9.26 ERBB2 KIT KITLG MTOR
25 erythropoietin-mediated signaling pathway GO:0038162 8.8 EPO EPOR KIT

Molecular functions related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.83 EPOR ERBB2 EWSR1 FAS RB1
2 nucleotide binding GO:0000166 9.71 CDK4 ERBB2 KIT MTOR
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.5 ERBB2 KIT KITLG
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.26 CDKN2A CDKN2B
5 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.16 ERBB2 KIT
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.13 ERBB2 KIT KITLG
7 kinase activity GO:0016301 9.1 CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
8 protein binding GO:0005515 10.18 CDK4 CDKN2A CDKN2B EPO EPOR ERBB2

Sources for Ewing's Family of Tumors

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....